Immune Dysfunction in Allergic Asthma

University of New Mexico (UNM)

Status: Completed

Conditions: Asthma

Treatments: Drug: Xolair

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00189228

UNMSCOR

R01HL044253 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.

Full description

Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.

Enrollment: 18 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Mild asthma, adults -

Exclusion criteria

children. on inhaled or systemic steroids

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

18 participants in 1 patient group

xolair

Experimental group

Description:

This is a single arm, parallel study examining differences of therapeutic outcomes of Xolair. Xolair is being examined as an intervention that might change the outcome of immunization.

Treatment:

Drug: Xolair